 This study examined the evidence used in health technology assessments, HTAs, of cell and gene therapies. It found that HTA bodies had different approaches to considering evidence, with some being more receptive than others. This suggests that there may be room for improvement in how these therapies are assessed. This article was authored by Michael Drummond, Oriana Chani, Julia Fornaro, and others.